Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 929 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Stereotactic radiotherapy Clear all

Conditions: Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Interventions: Immune checkpoint inhibitor, Radiation Therapy; Drug · Radiation
Lead sponsor: John L. Villano, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Pancreatic Cancer
Interventions: Stereotactic Radiosurgery (Cyberknife); Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Stanford, California

Conditions: Small Cell Lung Cancer Extensive Stage, Brain Metastases, Solid Tumor, Adult, Thoracic Cancer, Sarcoma,Soft Tissue, HNPCC
Interventions: Cohort A: Extensive Stage Small Cell Lung Cancer (ES-SCLC) Thoracic Tumor PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort B: Brain metastasis PULSAR (Personalized ultrahypofractionated stereotactic ablative radiotherapy), Cohort C: Sarcoma Pre-Operative PULSAR, Cohort D: Resectable Head & Neck Squamous Cell Carcinoma (HNSCC) PULSAR/SAbR; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Non-small Cell Lung Cancer
Interventions: Radiotherapy; Radiation
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Prostate Cancer, Prostate Adenocarcinoma
Interventions: Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost; Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older · Male only
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Metastatic Breast Cancer, Brain Metastases
Interventions: Nivolumab, Stereotactic Radiosurgery; Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non Small Cell Lung Cancer Metastatic
Interventions: osimertinib, stereotactic radiosurgery (SRS); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 8
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more

Conditions: Carcinoma, Renal Cell
Interventions: Stereotactic Body Radiation Therapy (SBRT), Microwave Ablation (MWA); Radiation · Procedure
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage I Pancreatic Cancer AJCC v6 and v7, Stage IA Pancreatic Cancer AJCC v6 and v7, Stage IB Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Pancreatic Cancer AJCC v6 and v7, Stage IIB Pancreatic Cancer AJCC v6 and v7, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7
Interventions: Capecitabine, Fluorouracil, Laboratory Biomarker Analysis, Pharmacological Study, Stereotactic Body Radiation Therapy, Zoledronic Acid; Drug · Other · Radiation
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Interventions: Azeliragon, Stereotactic radiosurgery, Corticosteroid; Drug · Radiation
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Malignant Neoplasm, Metastatic Malignant Neoplasm in the Bone
Interventions: Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography; Other · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Bone Metastases
Interventions: Radiation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions: Anti-PD-L1 Monoclonal Antibody MPDL3280A, Stereotactic Body Radiation Therapy; Drug · Radiation
Lead sponsor: Megan Daly, MD; Other
Eligibility: 19 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive, Oropharyngeal Squamous Cell Carcinoma, p16 Positive Neoplastic Cells Present, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Interventions: Durvalumab, Modified Radical Neck Dissection, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy, Transoral Robotic Surgery, Tremelimumab; Biological · Procedure · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Tachycardia, Ventricular
Interventions: Stereotactic ablative radiotherapy; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Magnetic Resonance Imaging, Memantine Hydrochloride, Neurocognitive Assessment, Stereotactic Radiosurgery, Survey Administration, Whole-Brain Radiotherapy; Procedure · Drug · Other + 1 more
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 227
States / cities: Phoenix, Arizona • Anaheim, California • Bellflower, California + 172 more

Conditions: Spine Metastases, Spine Stereotactic Radiosurgery (sSRS)
Interventions: Diagnostic MRI, Planning MRI, Simulation CT, QOL assessment, Brief pain inventory (BPI), sSRS in 1 fraction, sSRS in 2 fraction; Device · Other · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Prostate Cancer
Interventions: Degarelix, stereotactic body radiosurgery (SBRT); Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more

Conditions: Prostate Cancer
Interventions: Radiation Therapy; Radiation
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2024
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: SBRT, NSCLC, Non-metastatic
Interventions: GC4711 +SBRT, Placebo +SBRT; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Greeley, Colorado • Loveland, Colorado • Columbus, Georgia + 6 more

Conditions: Cancer Patients Receiving Stereotactic Body RTX
Interventions: SBRT; Radiation
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Prostate Cancer
Interventions: Leuprolide Acetate, Docetaxel, Bicalutamide, Radiation, Abiraterone Acetate; Drug · Radiation
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 80 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Brain Metastases, HER2-positive Breast Cancer
Interventions: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine; Combination Product
Lead sponsor: Baptist Health South Florida; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Benign Prostatic Hyperplasia
Interventions: Urolift; Device
Lead sponsor: Northwell Health; Other
Eligibility: 50 Years to 99 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Syosset, New York

Search by objective public record fields.

Priming Immunotherapy in Advanced Disease With Radiation

Cyberknife Radiosurgery for Locally Advanced Pancreatic Cancer

Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy

Whole Versus Partial Gland Boost During Prostate SBRT

Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases

A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain

Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer

Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases

18F-FDG PET-MRI for Planning and Follow-Up of Patients With Spine Tumors Treated With Spine Stereotactic Radiosurgery

A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Stereotactic Ablative Radiotherapy (SAbR) for Treatment of Ventricular Tachycardia (VT) Refractory Standard Invasive Ablation Techniques

Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability

Single- vs. Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases

Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer

Metabolomic Study for Localized Prostate Cancer

Phase I/II Study of SBRT and GC4711 for Centrally Located or Large NSCLC

Clinical Registry for Oligometastic Disease, Consolidation Therapy, Debulking Prior to Chemotherapy, or Re-Irradiation

A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

Urolift Pre-SBRT for Reduced Urinary Toxicity in Patients With BPH and Prostate Cancer.